Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Average Rating of “Moderate Buy” by Analysts

Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Free Report) has received an average recommendation of “Moderate Buy” from the eleven brokerages that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $195.90.

Several analysts have recently weighed in on JAZZ shares. Royal Bank of Canada cut their price objective on Jazz Pharmaceuticals from $200.00 to $191.00 and set an “outperform” rating for the company in a report on Thursday, November 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $225.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, November 29th. Truist Financial reaffirmed a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, December 4th. Barclays dropped their price target on Jazz Pharmaceuticals from $240.00 to $235.00 and set an “overweight” rating on the stock in a research report on Monday, January 29th. Finally, Robert W. Baird began coverage on Jazz Pharmaceuticals in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $160.00 price target on the stock.

Check Out Our Latest Stock Report on Jazz Pharmaceuticals

Insider Activity

In related news, Director Mark Douglas Smith sold 417 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $119.27, for a total transaction of $49,735.59. Following the completion of the transaction, the director now directly owns 6,888 shares of the company’s stock, valued at approximately $821,531.76. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of JAZZ. BlackRock Inc. increased its position in Jazz Pharmaceuticals by 3.3% during the 2nd quarter. BlackRock Inc. now owns 6,879,285 shares of the specialty pharmaceutical company’s stock worth $852,825,000 after purchasing an additional 222,801 shares during the period. Vanguard Group Inc. increased its holdings in shares of Jazz Pharmaceuticals by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company’s stock worth $825,705,000 after buying an additional 29,960 shares during the last quarter. Wellington Management Group LLP increased its holdings in Jazz Pharmaceuticals by 7.5% in the 1st quarter. Wellington Management Group LLP now owns 2,625,134 shares of the specialty pharmaceutical company’s stock valued at $408,654,000 after purchasing an additional 184,124 shares in the last quarter. State Street Corp grew its stake in shares of Jazz Pharmaceuticals by 1.8% during the second quarter. State Street Corp now owns 2,372,395 shares of the specialty pharmaceutical company’s stock valued at $294,106,000 after acquiring an additional 42,703 shares in the last quarter. Finally, LSV Asset Management lifted its position in shares of Jazz Pharmaceuticals by 2.4% during the third quarter. LSV Asset Management now owns 2,372,177 shares of the specialty pharmaceutical company’s stock worth $307,055,000 after purchasing an additional 55,630 shares during the last quarter. 88.15% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $124.24 on Tuesday. Jazz Pharmaceuticals has a one year low of $111.25 and a one year high of $152.90. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.67 and a current ratio of 2.06. The firm has a market capitalization of $7.82 billion, a PE ratio of 141.18, a price-to-earnings-growth ratio of 0.94 and a beta of 0.62. The stock’s 50 day moving average price is $122.07 and its 200 day moving average price is $127.82.

About Jazz Pharmaceuticals

(Get Free Report

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors.

Recommended Stories

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.